New PARTNER 3 trial 5 year data

Data from the PARTNER 3 trial continues to prove the Edwards SAPIEN 3 platform is the choice for lifetime management – from the index procedure and beyond.

  • Life: The only transcatheter heart valve with 1% death or disabling stroke at 1 year
  • Time: The only transcatheter heart valve with 90% survival at 5 years
  • Management: The only transcatheter heart valve with a THV-in-THV indication*

*For patients assessed at high-risk for surgical replacement.

Consistently demonstrating the results you need for the outcomes that matter

With patients of all ages living longer and having high expectations for their quality of life, lifetime management is increasingly important.

The first valve choice matters.

From outstanding outcomes and excellent durability* today to facilitating future interventions tomorrow, the SAPIEN platform is designed to deliver a TAVR experience an implanter can count on.

*Propensity matched analysis of intermediate risk patients using VARC-3 definitions of SVD and SVD related BVF at 5 years.

Join Edwards Connect

Our exclusive portal grants you access to our latest educational tools, resources, and more to help you communicate with your patients and referrers.

Connect with us

The Edwards SAPIEN platform brochure

When it comes to lifetime management, learn more about how the Edwards SAPIEN 3 platform is designed to deliver a TAVR experience an implanter can count on, starting with the index procedure.

View the brochure